Literature DB >> 14592910

Myasthenia gravis in individuals over 40.

Johan A Aarli1, Frederik Romi, Geir Olve Skeie, Nils Erik Gilhus.   

Abstract

Myasthenia gravis (MG) in individuals over 40 years of age comprises three groups: early-onset MG with prolonged disease duration, late-onset MG with thymoma, and late-onset of nonthymomatous MG. The clinical features do not differ between the three groups, except that early-onset patients with prolonged disease duration usually have a less severe disease. More than 60% of our MG patients are now more than 50 years of age, often with disease onset after age 40. Although 2 out of the 3 patients in Erb's original description had onset of myasthenic symptoms after age 40, this was apparently infrequent in 1879, when the disease was first identified. Onset of MG after age 40 is now common. For example, in our material, 88/184 (47.8%) had onset of MG after age 40. Eighteen (20.5%) had a thymoma. The female:male ratio in the early-onset group was 2.4:1, whereas it was 1:1.1 among those with onset after age 40. There was no human leukocyte antigen association for MG with thymoma. Antibodies to the acetylcholine receptor were detected in 88% of sera from nonthymomatous MG and in 100% of those with late-onset MG with thymoma. Antibodies to titin were found in sera from 85.7% of MG patients with thymoma (all age groups) and in 58% of nonthymomatous MG with late onset and acetylcholine receptor antibodies. Late-onset, nonthymomatous MG comprises two subgroups, one corresponding to delayed early onset and one immunologically similar to that seen in patients with MG and thymoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14592910     DOI: 10.1196/annals.1254.055

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Maintenance of immune tolerance to a neo-self acetylcholine receptor antigen with aging: implications for late-onset autoimmunity.

Authors:  Sue Stacy; Earlanda L Williams; Nathan E Standifer; Amanda Pasquali; Keith A Krolick; Anthony J Infante; Ellen Kraig
Journal:  J Immunol       Date:  2010-04-30       Impact factor: 5.422

2.  Dysphonia as first symptom of late-onset myasthenia gravis.

Authors:  Manuel Montero-Odasso
Journal:  J Gen Intern Med       Date:  2006-06       Impact factor: 5.128

3.  Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups.

Authors:  Liv Hapnes; Nick Willcox; Bergithe E V Oftedal; Jone F Owe; Nils Erik Gilhus; Anthony Meager; Eystein S Husebye; Anette S Bøe Wolff
Journal:  J Clin Immunol       Date:  2011-11-30       Impact factor: 8.317

4.  Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population.

Authors:  Angelina H Maniaol; Ahmed Elsais; Åslaug R Lorentzen; Jone F Owe; Marte K Viken; Hanne Sæther; Siri T Flåm; Geir Bråthen; Margitta T Kampman; Rune Midgard; Marte Christensen; Anna Rognerud; Emilia Kerty; Nils Erik Gilhus; Chantal M E Tallaksen; Benedicte A Lie; Hanne F Harbo
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

5.  The association of PTPN22 R620W polymorphism is stronger with late-onset AChR-myasthenia gravis in Turkey.

Authors:  Gizem A Kaya; Ayse N Coşkun; Vuslat Yılmaz; Piraye Oflazer; Yeşim Gülsen-Parman; Fikret Aysal; Rian Disci; Haner Direskeneli; Alexander Marx; Feza Deymeer; Güher Saruhan-Direskeneli
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

6.  Myasthenia gravis: MuSK MG, late-onset MG and ocular MG.

Authors:  Feza Deymeer
Journal:  Acta Myol       Date:  2020-12-01

7.  Efficacy and safety of double-filtration plasmapheresis treatment of myasthenia gravis: A systematic review and meta-analysis.

Authors:  Chaoying Liu; Peng Liu; Mei Ma; Hongxia Yang; Guoyan Qi
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

8.  Ectopic germinal centers in the thymus accurately predict prognosis of myasthenia gravis after thymectomy.

Authors:  Johannes Dunkel; Anni Tuulasvaara; Joona Sarkkinen; Antti Huuskonen; Sari Atula; Eliisa Kekäläinen; Sini M Laakso
Journal:  Mod Pathol       Date:  2022-03-25       Impact factor: 8.209

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.